Project background & objectives

In France, chronic respiratory diseases represent a major public health issue, affecting 10% of the population, with a higher prevalence among women.

Asthma affects almost 4 million people, resulting in 60,000 hospitalizations and almost 1,000 deaths every year. Chronic obstructive pulmonary disease (COPD), meanwhile, affects around 3.5 million people, with a worrying under-diagnosis rate: almost 70% of cases remain unidentified. By 2030, COPD will be the third leading cause of death worldwide.

In this context, the CUB Trajectory cohort has been set up to better understand and combat these pathologies. Its aim is to include patients with COPD or asthma, in order to assess the effectiveness of existing treatments, identify associated risk factors and optimize care pathways for patients suffering from chronic bronchial diseases.

3.4 bn

Public expenditure on health care management

+10%

French population affected by these diseases

+80

Variables of interest

The patient's voice

The Patients en Réseau association brings together patients and relatives affected by cancer, and was created on the basis of their experiences. Meet the Patients en Réseau association

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Participating centers

No items found.

Inclusion criteria & study variables

The CUB Trajectory project targets patients with chronic respiratory disease with a one-year follow-up. The cohort is made up of numerous variables covering the following areas:

Genre,
Date of birth,
vital status,

FAMILY NUMBER,
puberty etc...

FAMILY HISTORY OF AOH,
comorbidities,
AFFECTED FAMILY MEMBER(S) ETC...

DIAGNOSIS DATE,
DATE OF 1ST EXPERIMENT,
type of hereditary angioedema,

NATURE OF DEFICIT C1NH,
BIOLOGICAL CHECK-UP, ETC.

TREATMENT NAME,
DOSE,
FREQUENCY OF ADMINISTRATION,

SIDE EFFECT(S) ETC...

LOCATION OF THE CRISIS,
TRIGGERING FACTOR,
DURATION OF THE CRISIS,

TYPE OF TREATMENT,
treatment efficacy etc...

TYPE OF INTERCURRENT EVENT,
SHORT-TERM PROPHYLACTIC TREATMENT,
INTERCURRENT EVENT FOLLOWED BY A CRISIS ETC...

Genre,
Date of birth,
vital status,

DATE OF DEATH,
Cause of death etc...

SMOKING STATUS,
cannabis consumption,
vital status

DIAGNOSIS DATE,
METASTATIC AT DIAGNOSIS,
TNM STATUS AT DIAGNOSIS,

HISTOLOGICAL SUBTYPE,
metastatic sites,
MUTATIONS etc...

TYPE OF TREATMENT,
drugs used,
BETTER RESPONSE TO TREATMENT,

PROGRESSION ETC...

AGE,
SIZE,
WEIGHT,

SMOKING (PACKAGE/YEAR),
Allergies etc...

Patient with ENT symptoms,
cardiovascular disease,
nasosinus polyposis, etc...

Bronchodilator treatment(s),
NAME of bronchodilator,
dose of bronchodilator,

bronchodilator frequency etc...

Assessment of the number of exacerbations,
number of exacerbations,
reason for hospitalization etc...

GENRE,
DATE OF BIRTH,
vital status,

SMOKING (PACKAGE/YEAR),
Allergies etc...

SMOKING STATUS
ONCOLOGICAL HISTORY ETC...

Evaluation of eva,
Evaluation of das-28,
Anti-ccp ac results (u/ml),

Biopsy results etc...

symptomatic treatments
fund processing
biotherapies

stopping treatment etc...

Scientific Committee

No items found.

Key dates

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Posters & Publications

No items found.

Research projects

Here you will find all the study projects using the cohort. These projects comply with the regulatory framework and have been approved in advance by the cohort's scientific committee:

Patients

Why take part in the project?

Some of your medical and administrative data is collected when you are treated in a healthcare facility. This data is useful for the advancement of research.

This research, conducted in the public interest, aims to develop knowledge in order to develop new treatments or improve the overall management of patients suffering from the same disease as you. If you agree to your data being used for this study, you will not have to make any additional visits or undergo any additional examinations.

Only information already in your medical file will be collected. No directly identifying data (surname, first name or contact details) will be included in the cohorts.